Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Access and Evidence: Implications of the EPO Safety Debate (Part 2)

This article was originally published in RPM Report

Executive Summary

It looks like CMS is making its restrictive coverage policy on Aranesp and Procrit stick. That is a big hit to Amgen and J&J. It is also an important precedent for other manufacturers: CMS is demonstrating that it can deny coverage based on the absence of evidence-even when the therapy is the standard of care.

Related Content

Straight Talk About Cancer Drug Coverage
Cut to the Bone: Amgen Faces Further Aranesp Decline Ahead of Denosumab
Avoiding Another EPO: Amgen's Nplate Has FDA Restrictions, But May Escape Medicare Controls
Pharma's New Follow-On Strategy
EPO Market Stabilizes, But For How Long?
Biopharma: Reviewing 2007 to Forecast 2008
Relabeling EPO: Closing the Books on a Safety Issue, Opening a New Chapter at FDA
An Eye for an Eye: Lucentis and the New Pharmaceutical Value System
The Other Agency: CMS Shocks Wall Street-and Amgen Takes a Hit
Bad Blood: The Amgen/J&J Feud Takes a Perilous Turn


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts